cypc和vkorc基因多態(tài)性與華法林臨床個體化給藥doc-閱讀頁
2025-07-30 22:28本頁面
【正文】 enetics of oral anticoagulants. Pharmacogenetics. 2003。 63: 113541.[4]. Sinxadi P, Blockman resistance. Cardiovasc J Afr. 2008。 14: 174551.[6]. Wadelius M, Chen LY, Eriksson N, Bumpstead S, Ghori J, Wadelius C, Bentley D, McGinnis R, Deloukas P. Association of warfarin dose with genes involved in its action and metabolism. Hum Genet. 2007。 106: 232933. [8] Jorgensen AL, AlZubiedi S, Zhang JE, Keniry A, Hanson A, Hughes DA, Eker D, Stevens L, Hawkins K, Toh CH, Kamali F, Daly AK, Fitzmaurice D, Coffey A, Williamson PR, Park BK, Deloukas P, Pirmohamed M. Genetic and environmental factors determining clinical outes and cost of warfarin therapy: a prospective study. Pharmacogenet Genomics. 2009。 113: 78492.[10]. Li C, Schwarz UI, Ritchie MD, Roden DM, Stein CM, Kurnik D. Relative contribution of CYP2C9 and VKORC1 genotypes and early INR response to the prediction of warfarin sensitivity during initiation of therapy. Blood. 20
環(huán)評公示相關推薦
鄂ICP備17016276號-1